Dr. Patrick Aldrin‑Kirk

Dr. Patrick Aldrin‑Kirk is the CSO at rAAVen Therapeutics, a biotech company specializing in high throughput, rational AAV capsid engineering. Dr. Aldrin‑Kirk leads the engineering strategy for next-generation AAV capsids for gene therapy in the CNS, PNS, kidney, muscle, heart and pancreas. The development of next-generation capsids is aimed to increase cell specific targeting, increase efficiency, lower dose requirements and increase safety . rAAVen Therapeutics is currently leading the development of capsids targeting oligodendrocytes in collaboration with Myrtelle and for advancing therapeutic CNS capsids with Eli Lily-Prevail Therapeutics. Prior to joining rAAVen, Dr. Aldrin‑Kirk completed his PhD in neurobiology at Lund University, where he conducted work on engineering of AAV capsids for functional manipulation of transplanted dopaminergic neurons and retrograde AAV tracers for precise neural circuit mapping. In 2018, he joined the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen as a postdoctoral researcher, later becoming an Assistant Professor. There he conducted work on microfluidic-controlled brain-on-chip models to form regionally defined neural tissues.